Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:13:03 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Q:BEAM - BEAM THERAPEUTICS INC - https://beamtx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BEAM - Q1.525.46·26.451.526.52+1.797.21,348.034,41716,98325.63  26.68  25.2136.44  13.52519:38:38Jan 1115 min RT 2¢

Recent Trades - Last 10 of 16983
Time ETExPriceChangeVolume
19:38:38Q26.341.614
19:14:27Q25.61950.88951
18:48:18Q26.201.4770
18:39:22Q25.600.8710
18:31:57Q26.221.491
18:31:57Q26.221.4911
18:24:26Q26.341.612
17:48:13Q26.411.6810
17:06:45Q26.461.73150
17:06:11Q25.600.874

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-11 17:00U:BEAMNews ReleaseBeam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
2025-12-18 16:01U:BEAMNews ReleaseBeam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-12-09 11:57U:BEAMNews ReleaseBeyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
2025-12-06 08:00U:BEAMNews ReleaseBeam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
2025-11-12 07:00U:BEAMNews ReleaseBeam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
2025-11-04 07:00U:BEAMNews ReleaseBeam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
2025-11-03 09:00U:BEAMNews ReleaseBeam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
2025-08-25 07:00U:BEAMNews ReleaseBeam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
2025-08-14 07:00U:BEAMNews ReleaseBeam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
2025-08-05 07:00U:BEAMNews ReleaseBeam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
2025-06-13 07:00U:BEAMNews ReleaseBeam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
2025-06-03 07:00U:BEAMNews ReleaseBeam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
2025-05-29 16:01U:BEAMNews ReleaseBeam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
2025-05-14 09:30U:BEAMNews ReleaseBeam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
2025-05-13 07:00U:BEAMNews ReleaseBeam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
2025-05-12 16:01U:BEAMNews ReleaseBeam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
2025-05-06 07:00U:BEAMNews ReleaseBeam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
2025-04-05 07:00U:BEAMNews ReleaseBeam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
2025-03-27 16:01U:BEAMNews ReleaseBeam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration